The $19 central target is a calculated average rather than a published consensus. Five recent, individually attributed targets were reviewed: Wedbush at $16 (Hold), Wells Fargo at $18 (Overweight), BofA at $18 (Neutral, raised from $17 in November 2026), H.C. Wainwright at $20 (Buy), and Leerink Partners at $23 (Outperform). The mean of those five figures is $19.00, with a range of $16 to $23. Separate aggregator datasets include additional coverage and show a high near $25 and averages between roughly $18.80 and $20.30. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The spread is meaningful. Cautious, Hold-rated analysts such as Wedbush anchor the low end at $16, while buy-rated firms justify targets above $20 on the value of the pipeline relative to a market capitalization near $200 million. The pattern through 2026 has been predominantly downward revision—Leerink cut from $30 to $23 and Wells Fargo from $20 to $18—so the targets themselves reflect reduced, not heightened, expectations.
Keros Therapeutics (KROS) traded near $11 in mid-November 2026, not far above a 52-week low of roughly $9.10 and well below its 52-week high around $22.55. Reaching $19 from about $11 requires an advance of roughly 70%, a very large move for any stock over a typical research horizon.
The path depends almost entirely on clinical execution. Keros has no approved products and generates revenue chiefly from collaboration and milestone payments, including a Takeda partnership on its lead asset, elritercept (KER-050), which is in late-stage development for myelodysplastic syndromes (MDS) and myelofibrosis. The company is also shifting focus to its wholly owned asset rinvatercept (KER-065), now in a Phase 2 study for Duchenne muscular dystrophy. In the third quarter of 2026, Keros reported roughly $40 million in revenue, largely milestone-driven, and positive net income, while cash and equivalents stood near $259.5 million.
The strongest support is the gap between the current market capitalization—roughly $200 million—and the optionality embedded in the pipeline. Elritercept's late-stage, Takeda-partnered program offers near-term catalysts and potential milestone income, while rinvatercept represents a wholly owned growth avenue with initial Phase 2 data expected in the first half of 2027. A solid cash position, a modest $5 million share-repurchase authorization approved in September 2026, and a third-quarter earnings beat on both revenue and EPS (earnings per share) all help underpin the more optimistic targets. Analyst estimates were also revised higher by at least one firm following results.
The primary obstacle is binary clinical risk. A failure or delay in elritercept or rinvatercept trials would remove the value most buy-rated analysts are modeling, and any renewed financing need could dilute existing holders. The steady erosion of price targets throughout 2026 signals waning conviction, and the resignation of the company's CFO in mid-2026 adds execution uncertainty. With no meaningful recurring product revenue and shares trading near their 52-week low after a roughly 50% year-to-date decline, investor sentiment remains fragile, and insiders have been net sellers in recent quarters.
The chart reflects sustained downside pressure. Support sits in the $9–$10 zone, an area tested repeatedly in late 2026 and roughly matching the 52-week low, with the $10 round-number level acting as a psychological floor. On the upside, resistance is layered: the 50-day and 200-day moving averages have tracked near $11–$12, and prior breakdown areas in the $14–$16 range—roughly where the stock consolidated earlier in 2026—represent the first major hurdle on any path toward $19. Reaching the target would require not just a rebound but a decisive break back above these declining averages.
Analyst price targets for this stock generally reflect a roughly 12-month research horizon, though individual firms apply their own assumptions. Key items to watch include elritercept trial updates and regulatory interactions, initial rinvatercept Phase 2 data expected in the first half of 2027, quarterly cash burn and any changes to the Takeda collaboration, and analyst revisions following each data readout. Because Keros is pre-revenue on a product basis, clinical catalysts—not earnings multiples—will drive the share price. From what I see, this is important because clinical updates tend to move the stock more than any other factor.
For traders monitoring stocks like Keros, AI Daily Buy/Sell Signals offers an automated way to track shifting conditions. The system uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover new opportunities, monitor existing positions, and spot changing trends more efficiently than manual scanning allows. I find it helpful to cross-check signals here alongside my own review of the clinical pipeline before making any decisions.
The $19 target represents a calculated average of five current analyst price targets ranging from $16 to $23, and it requires a roughly 70% advance from a price near $11. The bull case rests on elritercept's late-stage, Takeda-partnered program and the optionality of rinvatercept, while the bear case points to a pre-revenue profile, a year of target reductions, and shares mired near their 52-week low. The wide spread between $16 and $25 shows analysts genuinely disagree about the pipeline's value. Whether KROS can reach $19 ultimately hinges on clinical data and milestone execution rather than valuation math, and investors should weigh that binary risk carefully. I'm watching this closely as the next set of trial updates arrives.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
KROS moved above its 50-day moving average on November 17, 2026 date and that indicates a change from a downward trend to an upward trend. In 37 of 45 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 82%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where KROS's RSI Oscillator exited the oversold zone, 26 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on KROS as a result. In 78 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for KROS just turned positive on November 17, 2026. Looking at past instances where KROS's MACD turned positive, the stock continued to rise in 35 of 44 cases over the following month. The odds of a continued upward trend are 80%.
Following a +19.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where KROS advanced for three days, in 224 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for KROS crossed bearishly below the 50-day moving average on November 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 59%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KROS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
KROS broke above its upper Bollinger Band on November 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for KROS entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.707) is normal, around the industry mean (3.592). P/E Ratio (-2.907) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (19.417) is also within normal values, averaging (442.120).
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. KROS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KROS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a biopharmaceutical company, which focuses on treatments for rare muscle diseases
Industry Biotechnology